Aptahem (publ) today announced that the company now enters a consortium together with Örebro University, the pharmaceutical development company AnaMar and Dalhousie University in Canada. The newly established consortium aims to evaluate new strategies to reduce inflammation, thrombosis and...
Read MoreAptahem (publ) today announce positive final results from the exploratory sepsis study with non human primates, the NHP study. The new preclinical results continue to support Apta-1’s multifunctional drug candidate potential within the treatment of sepsis. The completed comprehensive...
Read MoreAptahem (publ) announced today that a presentation entitled “Apta-1, a novel RNA aptamer, improves outcome in an animal model of sepsis” will be held at the World Congress of Intensive Care in Melbourne, Australia, October 14-18, 2019. This conference...
Read MoreAptahem (publ) announced today that the company has signed an agreement with a GMP-certified (Good Manufacturing Practice) contract manufacturer, LGC Group. LGC Group will manufacture the company’s lead candidate, Apta-1, for the concluding toxicological studies and the production is...
Read MoreAptahem (publ), a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved, announces today that the cooperation with the Seattle Children’s Hospital has now generated the...
Read MoreAptahem today informs that the company’s latest patent application has been made public. The patent application, which is an international PCT application*, is a merger of two previous Europe applications with the priority date 3 October 2017. The patent...
Read MoreAptahem (publ) announced today that Dr. Anders Bylock, Chief Medical Officer (CMO), is taking on another part-time position effective immediately. Dr Bylock engagement with the company as CMO as well as chairman of the scientific advisory board is unchanged...
Read MoreAptahem (publ) announced today that manufacture of its drug product has been delayed as a result of technical challenges. As a consequence, Aptahem anticipates that commencement of the planned clinical study for Apta-1 will be delayed. Aptahem reports that...
Read MoreAptahem AB (publ) today announces that the company intends to recall the outstanding amount of convertible notes held by YA II PN Ltd, a fund represented by the U.S.-based Yorkville Advisors Global (”Yorkville”). Through a mutual agreement, Aptahem will...
Read MoreIn the fight to save a person affected by sepsis every second counts – each hour that passes increases the risk of death with 8 percent. It is literally a race against time, a race that the healthcare services...
Read More